Nkarta Inc
6000 Shoreline Court
Suite 102
South San Francisco
CA
94080
United States
Tel: 415528-3392
Website: https://www.nkartatx.com/
Email: info@nkartatx.com
22 articles with Nkarta Inc
-
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
6/14/2021
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization Board of Directors for the 2021-2022 term.
-
Nkarta Announces June 2021 Investor Conference Schedule
5/25/2021
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at this upcoming investor conference:
-
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
5/13/2021
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the first quarter ended March 31, 2021.
-
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
5/6/2021
Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities
-
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
4/28/2021
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study NKX019 in patients with relapsed or refractory B cell malignancies.
-
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
3/25/2021
Continued progress in dosing of patients in clinical trial of NKX101, investigational CAR NK cell therapy engineered with NKG2D receptor, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Interim top-line data from NKX101 clinical trial expected by end of 2021
-
Nkarta Announces February and March 2021 Investor Conference Schedule
2/17/2021
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference February 26, 2021 Fireside chat presentation: 1:40 p.m. ET Cowen 41 st Annual Health Care Conference March 3-4, 2021 No presentation
-
Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.
-
Nkarta Reports Third Quarter 2020 Financial Results
11/12/2020
First patientdosed in clinical trial of NKX101, investigational NK cell therapy engineered with NKG2D-targeted CAR, in acute myeloid leukemia and myelodysplastic syndromes
-
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D
11/12/2020
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that the first patient has been treated in the first-in-human Phase 1 clinical trial of NKX101 for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes.
-
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
11/9/2020
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational allogeneic cancer immunotherapy that uses donor-derived natural killer (NK) cells engineered with a membrane-bound form of IL15 and a chimeric antigen receptor (CAR) targeting the CD19 antigen.
-
Nkarta Announces November & December 2020 Investor Conference Schedule
11/5/2020
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at these upcoming investor conferences
-
Nkarta Announces Leadership Changes
10/5/2020
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that Nadir Mahmood, Ph.D., Chief Business Officer of Nkarta, is assuming the expanded role of Chief Financial and Business Officer effective immediately.
-
Nkarta Announces September 2020 Virtual Investor Conference Schedule
9/8/2020
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced that it will participate at the following virtual investor conference
-
Nkarta Reports Second Quarter 2020 Financial Results
8/20/2020
Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021 Completed construction of cGMP clinical manufacturing facility Completed initial public offering of common stock on July 14, 2020, raising $289.8 million in gross proceeds Cash and cash equivalents of $341.8 million (pro forma) as of June 30, 2020, believed to be sufficient to fund operations into at least the second half of 2023 SOUTH SAN FRANCISCO, Calif
-
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesUnderwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million
7/14/2020
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the closing of its initial public offering of 16,100,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 2,100,000 additional shares of common stock, at a public offering price of $18.00 per share. The aggregate
-
Nkarta Announces Pricing of Initial Public Offering - July 10, 2020
7/10/2020
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $18.00 per share.
-
Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II
6/22/2020
Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential to achieve improved tumor control, optimized cell proliferation and moderate levels of cytokine accumulation SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell thera
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse® on the Berkeley Lights Beacon®
5/12/2020
May 12, 2020 12:13 UTC Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse ® on the Berkeley Lights Beacon ® CANTON, Mass.--( BUSINESS WIRE )-- Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveri